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fl&eefh. In this study we sought to iavestigate the elfect of 
intemdon with captopiil v&ldn 6 h of tbe onset of myocardial 
in6uction on left veatricalar volume aad clinical symptoms of 
heart fake in relation to iafarct size dnriag a l-year follow-up 
P- 
&&oandRemodelbigoftbehear4startsiatbeearlypbase 
of q yocardial iakctioa aad is associated witb aa adverse prog- 
~osls. Axsgiotensia~nverting enzyme inhibition started in tke 
suhacntc or Iatc phase after Iatpadid infardioll has hem shown 
to impme progaosis. 
i%Wiafiv. In the CaptoprIl aad Tbxwnbolysis Stady, 298 pa- 
tients with a first anterior myowdial iafaretion treated with 
intcavenons streptokinase wcrc randomized to receive either oral 
captoprIl(25 mg three times a day) or pbwebo. Tbe left ventric- 
aIar votume ladex was assessed by two-dimea&oaal Behocardtog- 
rapeYwithm24h,~oadsys3,10~98andafter1year. 
iTed&. A small hnt sigaIIcant iacrease ia left vent&alar 
Left ventricular dilation after myocardial infarction decreases 
prognosis (12). InitiaUy, left ventricular dilation is determined 
by infarct size and infarct expansion and, in the later phase, by 
increased wall stress and global ventricular enlargement (3). 
Therefore, the stage for left ventricular dilation is set in the 
early phase of myocardial infarction. Consequently, limiting 
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volume indexes was observed after 12 months. Usiag a raadom 
coc8icicnt model, no sigaiticaot treatment elf& on lefl veatricalar 
vobmes umld he detected. In contrast, when sarvival models we= 
used, the otmwrcne of left ventzkalar dilatioa was siga&aaUy 
Iowa in captopd-treated patie&? (p = 0.018). In addition, the 
imideocc of beart failure was lower in tbe captopril gcoap (p < 
0.03). Thii e&et appeared early aad was most obvioas in patients 
with a me&m-sized i&t (p = 0.04) aad was not preseat ia 
iargeInfa- 
tZm&&s. Veq early treatment with captopcil after myocar- 
dial infarcdon sigaificaatly redaces the occarrence of early dila- 
tion and the progression to beart failure. These data underscore 
the importance of early treatment. Fartbenaore, pattents with 
intermediate iafarct size be&t tbe most from this treatmeat 
Stratepy. 
(J Am CM GwlialI!J96;28:114-21) 
the infarct size by rapid restoration of blood Row to the area at 
risk is considered the most effective strategy to prevent dilation 
and subsequent morbidity and mortality (4-7). 
Angiotensin-converting enzyme inhibition, started within 1 
to 14 days after myocardial infarction, improves prognosis 
(8-12). Furthermore, long-term use of captopril in patients 
with asymptomatic left ventricular dysfunction after myocar- 
dial infarction reduces mortality, the incidence of heart failure 
and the rate of reinfarction (8). When captopril was given 
within 24 h after the onset of symptoms, a favorable effect on 
left ventricular remodeling was demonstrated in a small se- 
lected group of patients without thrombolysis (9). A modest 
but significant effect on mortality was observed~when captopril 
(10) or Iisinopril (11) was started within the first 24 h after 
myocardiat infarction. This became even more apparent in 
patients with clinical evidence of transient or ongoing heart 
failure if oral ramipril was administered between the seccmd 
and ninth day after myoczudial infarction (12). 
Immediate con-&ant administration of captopriI during 
thromboIysis in the early phase of myocardial infarction was 
cm-1097f96i51.2.00 
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evaluated in the Captopni and ThromholyG Study (CATS). 
The effect on ventricular arrhythmias, neurohonnones and 
clinical events during the first 3 months of follow-up for the 
two treatment groups was reporiel previously (13). The aim of 
the present study was to evaluate the time course of ventricular 
dilation as assessed by serial echocardiography during 1 year of 
follow-up and its relation to 1) the effect of double-blind 
treatment with captopril, 2) patient characteristics and infarct 
size at baseline, and 3) clinical outcome. 
Metbods 
The organization of the study was reported previously (13). 
In brief, CATS was a multicenter, double-blind, randomized, 
placebo-controlled study in patients with a Iirst anterior wall 
myocardial infarction treated with intravenous streptokinase. 
Patients were enrolled in 10 hospitals in The Netherlands. 
Evaluation of all echocardiographic measurements and deter- 
mination of enzymatic infarct size were done in central core 
laboratories. An independent Data Quality Committee re- 
viewed the data on clinical end points The study was approved 
by the Institutional Review Board of all participating hospitals. 
Stndy objectives. The primary and prespecilied objective of 
the present study was the assessment of the time-dependent 
effect of captopril, relative to placebo, on the preservation of 
left ventricular volume as measured by serial two-dimensional 
echocardiography 1,3 and 10 days and 3 and 12 months after 
myocardial infarction. In addition, post hoc analyses (closely 
parallel to the primary objective) of the relation between 
volume changes, patient characteristics, infarct size and clinical 
outcome were evaluated. 
Patlent eligibility. Patients were considered to be eligible 
for enrollment if a first anterior wall myocardial infarction was 
present and if they received thrombolytic therapy (15 million 
IU of intravenous streptokinase administered in 30 min) witbm 
6 h after the onset of symptoms. Witnessed oral consent was 
obtained, later conlirmed by written consent, alter the early 
phase of myocardial infarction. Diagnosis was based on the 
presence of characteristic symptoms of acute anterior myocar- 
dial infarction, with at least 0.1 mV of ST segment elevation in 
leads 1 and aVL or 0.2 mV of ST segment elevation in two 
precordial leads, or both, of the 12-lead electrocardiogram 
compatible with infarction of tile anterior wall and adjacent 
areas, including the septal and IateraI portions of the left 
ventricle. Patients were excluded if systolic blood pressure was 
over 2&l mm Hg or below 100 mm Hg, and if diastolic blood 
pressure was over 120 mm Hg or below 55 mm Hg. Additional 
exclusion criteria were reported previously (13). 
+Dx&ment ~rntncoI. Double-bhnd medication was initi- 
ated immediately on completion of the streptokinase infusion. 
Initially, an oral dose of 6.25 mg was given, repeated after 4 
and84andat16and24h,dosesof125mgand2Smg, 
respectively, were administered. Dose titration was continued 
provided the systolic blood pressure measured immediately 
beforethenextscheduleddoseofshtdyrnedicationwasabove 
or equal to 95 mm Hg. If tbe systolii blood pressure was below 
115 
Tahte 1. Reference Valdes (ml/m’) for Definition of Occurrence of 
Left Ventricular Dilation* 
vc4umc inch Mean 2 SD 
L&i vcrltricular end-systolic 213 + 8.4 
Left wmilxlar enddiastoiic 51.7 c 113 
‘See Me~ltals. 
95 mm Hg, the study medication was withheld until the next 
dosing time. The target maintenance dosage of the double- 
blind study medication was 25 mg three times a day, adminis- 
tered from day 2 to 12 months after the myocardial infarction. 
During the 12 months of double-blind therapy, concomitaat 
therapy with calcium antagonists, beta-adrenergic blocking 
agents or nitrates was instituted only for q&tic indications 
(e.g., angina and hypertension). However, the protocol did not 
prohibit the use of beta-blockers for seamdary prevention. 
Also, the use of aspirin was at the discretion of the local 
investigator, with a recommended dose of 80 mg. 
EebncardIography. Par echocardiographic measurement 
of left ventricular end-diastolic and end-systolic volmnes, api- 
cal t xo and four-&amber views were obtained md recordings 
made with respiration held at end-expiration or partial inspi- 
ration. Patient angulations, transducer position and respiratory 
phase were recorded. End-diitolic and end-systolic frames 
were outlined from both apical views using the Dataview 
Microsonics cardiac analysis system (Nova Minim). Left 
ventricular volumes were cakxdated using tbe biiane (modi- 
fied) Simpson’s rule. The mean of two measurements on 
consecutive cycIe-s was taken for each examination. Left ven- 
tricular end-diastolic volume index and left ventricular end- 
systolic volume index were derived from body surface area, 
which was estimated at each time point. All initial e&xx&o- 
graphic determinations of left ventricular volume were per- 
formed within 12 to 24 h after admhGonandatleast4hafter 
the last dose of double-blind study medication. Ail subsequent 
echocardiographic determinations obtained on day 3, before 
diiargeandat3and12monthsweremadenoearlierthan 
8 h after tbe dose of double-bhnd study medication To ensure 
the return to the same echocardiographic view, a metbod of 
locating the transducer in reference to bony k&marks was 
applied. Lateral rotation and elevation of the upper body were 
noted and maintained at subsequent studies. 
Detinitionofleftven~dilstion. Theleft ventricular 
volumes of all patients with small enzymatic infarct size, i.e, 
a cumulative alpha-hydroxybutyrate dehydrogenase release 
<730 IU/Iiters, which represents tbe lower tercile of all 
randomized infarct sizes, were pooled. This group of patients 
showednochangehetweeathefkstandlast~hic 
evaluation. Mean left ventricuk end-diastolic and end-systok 
volume indexfs and cormpond@ standard deviations of this 
reference grovp were used as reference values for our detini- 
tionofleftventriaJfardilationinthecATSstudygroup(Table 
1). Subsquentiy, all indkidwl end-systolic and end-d&A 
volume indexes at each time point were compared with this 
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reference value. A ventricle was considered dilated if the 
following two conditions were fullilled: 1) The left ventricular 
vohrrne index (either end-systolic or ,end-diastolic) was 1 SD 
above the reference value. Thus, either the left ventricular 
end-systolic volume index had to be above’ 29.7 ‘ml/m’ or the 
left ventricular end-diastolic volume index had to bc above 63 
mI/m*. 2) The sum of end-systolic and enddiastolic volume 
Sexes had to be 1.5 SD above the sum of the respective 
reference values. ‘~bus, tbe sum of left ventricular end-systolic 
and end-diastolic indexes should bc above 87.8 ml/m*. 
This dilation criteria appeared to be robust because varia- 
tion of the criteria between 0.5 and 1.5 SD generated compa- 
rable results. The timing of dilation was assumed as halfway 
between the visit showing dilation and the previous visit 
witbout dilation. 
Iihqmatie infarct six. Infarct size was expressed as the 
cumnlative release of alpha-hydroxybutyrate dehydrogenase 
activity per liter of plasma within the first 72 h. This was 
calculated from serial plasma alpha-hydroxybutyrate dehydro- 
genase determinations from blood samples taken twice daily 
during the lirst 5 days, as described by van der Laarse et al. 
(14). These investigators demonstrated that this method was 
independent of the result of thromholysis. Infarct size was 
considered small if enzyme release was less than 730 Wliter, 
medium if enzyme release was between 730 and 1,460 III/titer 
and large if enzyme release was more than 1,460 WIiter. 
Cutoff points were derived from terciles of all randomized 
infarctsixes. 
uf beart falbue. The presence of heart failure 
was based on the clinical judgment of the principal investiga- 
tors All patients in whom diuretics or digoxin, or both, was 
started, in whom open-label treatment with an angiotensin- 
converting enxyme inhibitor was started, whose hospital stay 
was prolonged or who had to be readmitted to the hospital 
owing to the presence of symptonr~ of heart failure were 
considered to have heart failure. Hospitalization was consid- 
ered prolonged if the duration was above the normal hospital 
stay for myocardiaI infarction, which was on average 9 days. 
Furthermore, the reason for this !onger hospital period had to 
be expl&Iy recorded in the Case Record Form. All patients 
with prolonged hospital stays because of signs and symptoms c’ 
heart fake were evahmted by the Data Quality Committee. 
All other causes for prolonged hospitalixation were excluded. 
!&&h&s. According to the intention-to-treat principle, all 
outcome analyses were based on the treatment group to which 
the patients had been randomly assigned. A random coetIiciet,t 
model was used to analyxe e&cardiograph&z data for the 
following reasons: 1) one or more echocardiogmms were not 
evatuaMe for a substantial group of patients owing to a lack of 
eebogeneity, 2) left ventricular end-systolic and enddiastolic 
v&me indexes varied snbstautiaUy between patients at entry, 
and3)eehocardiogramswerenotobtainedatexactlythesame 
pointsintime.Therandomcoe&ientmodelalloweda 
~betweenthehvotreatmentgroupsusingaUeeho- 
CaKUugraphic da@ accounting for dilferences in left ventricu- 
Iar volume index between patients at entry (random intercept) 
and for differences in time in response to treatment within 
patients (random slope). El values were approximated by a 
chi-square distribution, based on model differences in twice the 
negative log likelihood (15). The occurrence of dilation, ac- 
cording to our definition, and the incidence of heart failure 
were analyzed using survival techniques evaluated by the 
log-rank test. 
If not otherwise indicated, continuous variables other than 
left ventricular volumes were compared using the Student t test 
and categorical variables using Fisher exact test (two-tailed) or 
the chi-square test. Results were considered statistically signif- 
icant if :k; i values were less than 0.05, using the two-sided 
level of significance. 
The statistical software of Ml& version 2. was used to 
analyze the random coefficient model. The remaining statisti- 
cal analyses were performed with SAS, version 6.08. 
Results 
A total of 298 patients were enrolled in CATS, with 149 
patients allocated to each treatment group. The time from 
onset of symptoms to the time of streptokinase infusion was 
166 +- 70 min in the placebo group and 163 -C 76 min in the 
captopril group. The time of the tirst dose of study medication 
from onset of symptoms was 213 ? 76 min in the placebo 
group and 212 5 86 min in tbe captopril group. A complete 
clinical follow-up over the 1Zmonth period was obtained in 
245 patients (52.2%). Twenty-three patients (8%) died and 30 
patients (13 in the placebo group and 17 in the captopriI 
group) were withdrawn from the study during the l-year 
follow-up period. Twenty-four hours after randomization, the 
target dose of 25 mg three times a day was reached in 95% of 
patients (94% for the placebo group and 95% for the captopril 
group). At discharge, 89% of all randomized patients were still 
receiving the study medication (89% for the placebo group and 
89% for the captopril group). At tbe end of the 1Zmonth 
follow-up period, 89% of patients with complete clinical 
follow-up were still taking the study medication (92% for the 
placebo group and 85% for the captopril group). At discharge, 
20.1% of the patients were receiving aspirin and 11.1% were 
taking coumarin. 
The clinical characteristics of the two groups were compa- 
rable at baseline (Table 2), although previous hypertension 
was more frequent in the captopril group. 
Dphic IIIeRaurementa d Ml VenbicuIar vol- 
umes. Appropriate measurement of left ventricular volume 
index on at least one time point was available in 263 (88.3%) 
of the randomixed patients (Table 3). Characteristica of pa- 
tients with available echocardiograms and caIculated infarct 
sizes, which were used in the random coefficient model, in 
comparison to the remaining randomized patients, are pre- 
sented in Table 4. ‘Ibe most important diierence between the 
groups is the gender diiiution. 
Left ventricnlar end-systolic and end-diastolic volume in- 
dexes during the l-year follow-up period for the two treatment 
groups are depicted in Figure 1. The total study group showed 
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Table 2. baseline Characteristics of the Two Treatment Groups 
Placebo captopril 
GtOUp &OF 
(n = 149) (n = 149) 
&W 
Mawrentale m 
clinical history (J) 
rscheukheartdisease 
nyperiension 
Diabems mellitus 
(2ttrmn smoker 
KiUip dass (%) 
I 
II 
Cotteomilant medic&m at 
randumhtiml (%) 
Beta-bhxkets 
CaIcium antagmti.sts 
DhretkdNg5 
Nitrates 
systolic BP (mm Hg) 
Diastolic BP (mm Hg) 
Heart rate (mit-‘) 
6019 
8wm 
8.0 9.4 
16.1 27.5* 
9.4 9.4 
57.7 67.1 
1s 16 
25 24 
16.’ 22.2 
14.8 12.8 
10.7 12.8 
10.7 9.4 
125219 lzsf21 
77 e 12 772 13 
81 5 14 83 2 16 
59510 
rn.vJ 
‘p = 0.017 by Faber exact test (hwtaikd). Data presented are mpan 
value -t SD or percent of patients. BP = bluud pressure. 
a small but sign&ant increase in both left ventricular end- 
diastolic and end-systolic volume indexes of 6.7 ml/m’ (95% 
confidence interval [CI] 3.4 to 9.9) and 4.8 ml/m* (95% Cl 2.2 
to 7.3), respectively, over the 12-month follow-up period. 
However, analysis with the random coeikient model revealed 
no sign&ant effect of tieatment with captopiil uii changes in 
ventricular volume over the first 12 months after myocardial 
infarction when compared with placebo. Factors that sign& 
candy influenced left ventricular volume index are indicated in 
Table 5. Infarct size and time were among the most powerful 
Table 3. Left Ventricular End-Systolic vd End-Diastoli, Volume 
Indexes (mean * SD) for Each Treatment Group and at Each Tii 
Point During the One-Year Follow-Up Period 
lime placebo capopril 
WV) Group Grwp 
LVEW (ml/m*) 
0.3 + 0.4 25.7 z 9.5 25.7 + 10.8 
2.2 i: 0.4 26.2 f 9.8 24.6 2 9.1 
8.7 + 3.9 28.7 2 11.3 26.6 _t 11.9 
98.3 f 16 30.0 -t 15.1 28.9 % 15.7 
369.12 20.2 295 2 14.8 30.0 2 16.1 
LVEDVi (ml/m*) 
03 + 0.4 56.4 c 13.3 56.1 f 142 
22 i: 0.4 57.2 2 132 54.0 -+ 11.8 
a7 -c 3.9 60.4 c 14.4 59.1 + 15.6 
983 + 16 62.7 f 11.4 61.9 + 19.4 
369.1: 202 62.8 + 17.6 61.4 2 21.1 
LVESVl=leRvenuicularqld+Aicvohlmeiode&LVEDVl=lefl 
veatrindaeaddivdumeiudea. 
VAS GUT ET AL. 
CAPTOPRIL AND THROMBOLYSIS STUDY 
Table 4. Baseline Characteristics of Patients Included in Versus 
lhose Excluded From Random CoeEicient Model 
Age w 59 c 9 62 I 10 
Male/fen;& (%) 1822 57143’ 
Clinical histq (%) 
kcbemic heart disease 9.1 5.7 
Hypertemiull 22.1 20.0 
Diabetes mcllius 8.8 14.3 
Current smoker 62 7 600 
Killip class (SE) 
1 77 @I 
11 23 40 
coammitatlt ltteacadon at 
randomization (a) 
BcIa-blockers 20.5 h6 
Calcium antago&ts 13.7 143 
Diuretic drugs 11 17.1 
Nitrates 10.3 a6 
Syxtolic BP (mm Hg) 127 -’ 20 124 r 18 
Diastolii BP (mm Hg) z-2 13 77-t 11 
Heart rate (min-‘) 825 15 84r 13 
‘p = 0.012 by Fbhrr exact test (two-tailed). Data presented are - 
value f SD or percent of patients. BP = blood pressure. 
determinants of left ventricular enlargement. The time factor 
was nonlinear and the largest changes occurred in the early 
phase. Additional factors associated with left ventricular vol- 
ume indexes were different for systolic and diastolic volumes 
(Table 5). 
Ooclureace of left ventricnlar dilatha If, at any point in 
time, dilation according to our definition occurred, the patient 
remained dilated during the following echocaniiographic eval- 
uations. This enabled us to use survival techniques to evaluate 
treatment ekts on the occurrence of left ventricular dilation. 
Figure 2 shows that a large percentage of left vent&&r 
dilation ahzady occurred in the in-hospital phase of myocar- 
dial Suction. Furthermore, during this period, a sign&ant 
e&t of captopril treatment on the incidence of dilation was 
already apparent, which was maintained during the one year 
follow-up. 
EEqmaticInfarctsixed~.setumcrc- 
atine kinase and alpha-hydroxybutymte dehydrogenase activity 
were determined serially in 86.9% of patients. A wide range of 
infarct sizes was present in thii group, as can be seen in Tab% 
6. Figure 3 represents the change in left ventricular end- 
diastolii and end-systolic vohunes measured over the 12- 
month follow-up period for small, intermediate and large 
infarcts The change in left ventricular volume index for the 
different strata was predicted by the statistical model, a~ 
indicatd by the sotid lines (Fig. 3). The effect of treatment 
with captopd in the three dilferent strata on the occurrence of 
dilation is indicate in figure 4. The occurrence of dilation 
increased with kreas&g5kC+oprilreducedtheoccur- 
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0cAPl.m 
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Ffgure 1. Mean left ventricular end-systolic volume index (LVESVf) 
(A) and mean left ventrfcufar enddiastofii volume index (LVEDVf) 
@) during the l-year follow-up period for the captoprikreated 
patients compared with the placeho group. 
reuce of dilation in smnff infarcts and significantly irt medium 
iofarets. However, dilation was not prevented by captopril in 
the large infarct group (Fig. 4). 
Clinkal eve&. The incidence of cliical events is summa- 
rixed in Table 7. The mortality rate was low (8%), with no 
significant difference between the two treatment groups. The 
incidence of coronary revasadarixatioo procedures tended to 
be lower iu the captopril group. Episodes of reittfarctioo 
occurred in 21 patients, 7 of which were within 72 h, in 4 cases 
related to percutaneous traoshrminal coronary angioplasty. 
Interestingly, the incidence of heart failure showed the 
saore pattern as the occurrence of ventricular dilation during 
the l-year follow-up (Fig. 5). Furthermore, a conrparab~e, 
tigoilicaut treatment e&t was present (p = 0.036). This 
treatment effect on progression to heart failure was similar to 
the oeeurrence of diIatiou-that is, confmed to the patients 
with medium-sixed infarcts (Tabie 6). 
Adverse vents. Adverse events in the captopril and pla- 
cebo treatment groups were previously reported in the parent 
trial and were distriiuted simkly. 
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Table 5. Factors Significantly Determining Left Ventricular 
End-Systolic and End-Diastolic Volume Indexes Acccording to the 
Random Coefficient Model* 
Vatiabk 
LVESVI LVEDVl 
cwmcient p Vable CoeRieient p value 
constant 18.40 < o.m1 47.00 < 0.m1 
Tie (days) (In) -0.19 < O.awol 0.18 < O.ooool 
Infarel Gze 
Medium 3.0 0.02 35 0.06 
bv 9.2 < o.oooo1 9.8 < O.wKJl 
TxI 
Medium 0.9 0.009 1.0 0.03 
Large 2.2 < o.oom 2.9 < O.ooM)l 
Male 3.2 0.01 5.00 0.03 
CHF 2.40 0.01 - NS 
zahel ACE - 5.5 0.004 NS -6.99 - 0.01 NS 
Urn of nitrates - NS 3.3 o.M)3 
Study mdicarion -0.11 0.92 -0.44 0.76 
*See text for details. ACE = angiotensinanverting enzyme inhibitors; 
CABG = coronary artery bypass graft surgery; CHF = congestive heart failure; 
LVEDVI = left ventricular enddiiolic volume index; LVESVI = left vent& 
ular end-systolic volume indea; T X I = inleraction term of time and infact size. 
Discussion 
The present data demonstrate that io our group of patients 
with a wide range of infarct sizes, left ventricular end-systolic 
and end-diastolic vohmres increased only slightly when all 
patients were considered together. Furthermore, after 12 
months no sign&cant effects of treatment on left ventricular 
volume indexes were found between the total raodonrixed 
groups. When patients were characterized io terms of the 
presence or absence of left ventricular dilation, a sign&ant 
effect of treatment was observed. This effect on the incidence 
Fff 2. Curves representing the absence of dilation during the 
l-year follow-up period for the captopril-treated patients compared 
with the placeho group. 
1.0 
0.9 
il 
0.3 
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0.4 
0.3 1 
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T&k 6 Infarct Sii, Ckcurrenee of DiJation, Left Ventricular End-Systolic and End-Diastolic Volume Indexes and Heart F&we for Patients 
with SmalJ,’ Mediumt and Large* I&ret5 in Both Treatment Groups 
JTweb3 captopril 
AJJbHBDH Alpha-HBDH 
Jnfant sire (mew 2 SD) Dilaticwl (5-h) CHF f’t) (mew f SD) Dilation (%l CHF (F, 
smau(o=s7) 414r199(a=40) 30 2.5 383~2ll(n=47) 19 21 
Mediaa(n=88) 1,112 + 202 (a = 43) 63 36 1,037 ? 213 (n = 45) 409 Ill 
Large@=@9 2,515 + 1.035 (n = 47) 87 45 2,327?614(n=41) a5 43 
*Alpha-by- dehydrogeaase (AlpbzHJJDH) 030 lU/liter. tAlJh-hydmxybuyaw debydrogenace 730 to 1,460 JlJlliter. #hhydroxybutyrate 
delydmgeaase >I,460 JlJfiiter. @aificmt redactioa versas placebo; p = 0.036 by Faber exact test. @wterliae slgnififanr versus phcebo; p = O.M7 by Fish & 
teat. CHF = eongwtive heart failure. 
of dilation coincided with a significant effect on the progression 
to overt heart failure. Treatment effects appeared to he largest 
in the oatients with intermediate-sized infarcts, which conlkms 
in a clinical setting the early observations by Pfeikr et al. (16). 
Figwe 3. SoIid eIrdes represent mean (?SEM) left ventrictdar end- 
systolic volume index (LVESVI) (A) and mean left ventricular end- 
diastolic volume index (LVJZDVI) (B) for the total study group, as 
measured during the l-year follow-up period for small (bottom 
line), medium (middle line) and large (top tine) infarct sizes.. l&es 
are calculated by the ML3 statistical model using the variables from 
Table 5. 
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DAYS AFTER INFARCTlON 
They showed in a rat infarct model that the largest treatment 
effect of captopril occured in the group with medium-sized 
infarcts after long-term follow-up. 
Quadative tw~nsional cc- has provided 
importmt insights iota th mechanism of left ventrkilar eolarge- 
ment and modulation of this enlargement by sngiotensin- 
amvert@enzymeinhiMors(l7).However,mostofthesestu&s 
usedpatientsselededinthesubaMephase(Y)orwe~partof 
largerinterventioatriakusingdinkAendpoints(l8).I’hedesign 
ofthepreaentm~diJTel5inmaIfy~t~ 
frommostoftheechocardiographicpostinfarctionioterwntioo 
trial5 mabating angiotersinawverling en2yme irhibkm. Fii 
patientswwellotselectedontheba5isofthcircardiac- 
Aucollsal~iveanterioTmyocardialiufarctionstreatedwidl 
streptolrinasewcrcinduded.‘lberefore,dtecA~patientsbad 
botbsmauandlargeinfkctsaodthlIshadiowar4dhighriskof 
subsequent d&ion and d&-al deterioration. This eaabled us to 
evaluate treatmat e&us in different risk sbata second, capto- 
prilwasadministered~,within6haftertheonsetofsympt~ 
-~Witllthrombdytictht?rapy.LeftVCtltricularCO- 
largementhasbeer:sharmtostartvery~aftertheonvtof 
myocardial inkiction. In this early phase, stretching of the infarct 
Fere 4. Curves representing the absence of diii duriag the 
l-year follow-up period for tk capfopril-treated patients coqared 
with the placebo group and for diierent infarct sizes. 
120 VANGIISTETAL 
CAPTOPRIL AND THROMBOLYSIS STUDY 
T&e 7. Clinical Eod Points 
PlaQbO Captopd 
End P&t (n = 149) (n = 149) 
Mortality 10 13 
Heartfailure 53 39 
PEA 42 34 
CABci I1 12 
Reillfaretion 6 15 
Aoy~~ 92 86 
CA%3 = wronaq artery bypass graft surgery: PWA = percutaneous 
transhJminal coronaly angioplasly. 
zone due to slippage of the necrotic myofibrils occurs (3). 
Experimental studies have shown that angiotensinconverting 
enzyme inhiition may improve smvival of the ischemic myocyte 
(19,2O). To achieve the beneficial effect it is critical that treatment 
&tartedveryearlyandthatthedmgisabletoreachthemyocytes 
atlisk.Intbe~settio&thissituationmaybestbecre;ttedif 
tmtment is initiated within the thmmbolytic window. The early 
phase of left ventrieuar dilation is a regional phenomenon 
located pmhinandy in the infarct-related zone. This is followed 
by a second phase of dilarion, which involves the entire ventricle, 
and may contimte for months after the i&7&n. The latter 
pA-wes~besidesdila~ofhype~ofthenonin- 
farct-relatal zone in response to the loss of contractile elements 
and increased wall stress To evaluate and compare treatment 
e@edsinthesetwope&ds,thepresentstudyusedseriafech~ 
~withobservationsintheeatlyphase(ondaysland 
3andatd&argefromthehospital)andinthelatephase(at3 
and 12 months). 
Wtat explaim the discrepancy between the effect of capto- 
pril on the occurrence of dilation and the lack of effect of 
captopril on the average left ventricular volume index? The 
txmecutive enroBment of patients in CATS yielded a broad 
range of infarct sizes from oniy minor damage to very large 
infadons. The random effect model revealed that infarct size 
is the most powerful determinant of volume expansion, with 
the highest incidenoe of dilation (86%) occurring in the group 
with large infarc& and the ieast amount of ventricular eniarge- 
ment (25%) oamring in the group with small infarcts. Fur- 
thermore, the distriiution of left ventricular volumes within 
each group shows a broad range, which is progressively increas- 
ing toward high dues in patients with large infarcts. If the 
detrimental process of dilation occurs, it continues in the late 
pb as a gradual process of ongoing dilation. The difference 
in the average extent of dilation in the two treatment groups, 
combined with the. large range of ventricular volumes, may 
have been too SIttall for a treatment elfect on average ventric- 
ular volmne index to appear. The study was powexed to detect 
diEere0ces in left vetMdar vohme index >8 mi/m’ belween 
the treatment groups after 12 months. A study group of at least 
700 patients would have been required to establish whether the 
dBWncesfoundinaveragevenGc&r~umeswereduetoa 
~~~e~~~,~~~~~~~r- 
~~~~~~~-~~t~.~~ 
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Figure 5. Guves representing the absence of heart failure during the 
l-year follcw-up period for the captopril-treated patients compared 
with the placebo group. 
end of the 1Zmonth follo*v-up period, 31% of the patients had 
developed clinical symptoms of heart failure and were treated 
with open-label captopril. 
Clinical end points. After 12 months, the clinical outcome 
between the two groups of patients was similar, except for a 
significant reduction in the incidence of heart failure (p = 
0.036). The magnitude of this reduction is comparable to the 
figures reported by Pfeffer et al. in the Survival and Ventricular 
Enlargement (SAVE) study (8), the Studies of Left Ventricu- 
lar Dysfunction (SOLVD) investigators (21), the Second Co- 
operative North Scandinavian Enalapril Survival Study group 
(CONSENSUS 11) (22) and the Acute Infarction Remipril 
Efficacy (AlRE) investigators (12). This observation, as ex- 
plained previously, was not paralleled by a reduction in aver- 
age left ventricular volumes, i.e., attenuation of left ventricular 
remodeling in the total population. However, the time course. 
of individual dilation and the effect of captcpril on this 
phenomenon showed a comparable pattern. This suggests that 
captopril prevents the progression to heart failure in low and 
medium risk patients by preventing the occurrence of dilation. 
A statistically significant effect of captopril on progression of 
dilation was only demonstrated in patients with medium-sized 
infar!!. If dilation had already occurred, progression to symp 
tomatlc heart failure was not significantly affected by treat- 
ment, as can be observed in the group with large infarcts. 
Apparently, in this group the effect of captopril on dilation and 
subsequent progression to heart failure were offset by the 
magnitude of myocardial damage. 
implications for clinical praetlce. Before any implications 
for clinical practice are derived from this study, it should be 
taken into account that the study group represents -30% to 
4O%,of the total infarct population, because only first anterior 
myocardiii infarctions treated with streptokinase were ran- 
domized. The design of CATS focused on intervention in 
additiontothmmbolys&asamtmstedtomostotherstudies, 
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in which angiotensin-converting enzyme hthtbitors were stud- 
ied for secondary prevention after myocardial infarction. ‘Ihe 
outcomes of the recently presented Fourth International Study 
of Infarct Survival (ISIS-4) (10) and Third Gruppo Italiano per 
lo Studio delia Streptochinasi nell’htfart Miocardico 
(GISSI-3) (11) studies indicate a modest but favorable effect 
on mortality during the first weeks after infarction if treatment 
is started within 24 h. Based on the outcome of these studies. 
the investigators advocated the early use of angiotensin- 
converting enzyme inhtbitors. However, them s: tidies revealed 
no mechanism or insight into which patients be&t most from 
treatment. The pnsent study reemphasizes that dilation is a 
very early process and that the effects of treatment are already 
apparent at this stage. Therefore, we suggest that treatment 
should be started as early as possible, preferably within the 
thrombolytic window. Based on the results of CONSENSUS II 
(22), in which an aggressive intravenous treatment strategy 
with enalapril was -used, we suggest that early treatment should 
be started with a lo:- :‘+se. of oral captopril in patients who are 
hemodynamicaity stable, i.e., those with a systolic pressure 
>lOO mm Hg. If well tolerated, this dose may be increased 
more rapidly thereafter. If during the hospital period infarct 
size appears to be small and left ventricular volume index 
within the normal range, discontinuation of treatment may be 
considered at discharge. 
4. Third International Study of infarct Survival Collabotative Grcup. IS&~: a 
raadormzed compmimn of streptdriaase vs. tissue plasmiin activator K. 
anistreplase and of aspirin plus heparia vs. aspirin abe among 41,299 ~asa 
of suspected acute myocatdii infarction. hcet 1992239~7%~. 
5. Warren SF., Royal HD, Markis JE, Gmssnan W, McKay RG. The course 
dMtVWiZlkU~ahamyaardialtiCtiw:idl-dittbld- 
rdatid artery and - of ammar, tlmm~lysir. J Am CoU Cardioi 
198?$11:12-9. 
6. thppo lcaliaao per lo Studio della Streptaehinasi nell’lafarto hfhrdicu 
(Glssl). Euecliveness d iJurawnous thmmborytic treatmeat in acute myw 
cardial infarctfun. lancet 19a6$397-402. 
7. Second htemational Study of Infarct Survival Collabwative Group. Ran- 
danized trial d intraveMus streptokinase, oral aspirin, butb or wither 
among 17,187 cases ofslqsted acute mywa&l infaraiw: lSlS-2 Lancet 
1988Qw9-60. 
8. Pfekr MA, Braunur;lld E, Moyt L-l, et al. Effect of capqil adminisuath 
on infarct expansion, left vetilar remodeliig and erei-cise capacity after 
acute myocardial irdamim Am J Cardioi 1991;68:713-8, 
9.OldroydKG,~MD,RaysG.EffectsoIeartyQptopril~tiooon 
infarct expmim, left vemricdar remodeling and exerdse cap&y after 
acute lllyockdial idtin. Am J cardiol1991;6%:713-8. 
10. FourthlntewiottalStudyofhfarusurvivalcdiaborativeGrcu9 F.,tutb 
Intematimal Study of bfatct Survival: a randomized factall trial aacging 
earlydQpoprild -,andiabavewusmagnaiumsu$hate 
in58,050patknsdthsqec%edaatteqocardb3ir&cthImet 
1995;345.%69-85. 
Condushms. The CATS trial provides important eehocar- 
diographic data on the mechanism of dilation and the effects of 
early oral captopril administration in patients with acute 
anterior myocardiaI infarction receiving thrombolysii. Despite 
the outcome of the recently presented large-scale trials, several 
questiom remain unanswemd.Thepresentdatashowthatven- 
tricular enlargement in thii group of patients is mostly an e&y 
phenomenon. Treatment with captopril prevents the pmgrekm 
to dilation especUy in patients witb an intermediate-sized 
infarct size, who benefit from early treatment. Patients with huge 
idarcts still dilate despite treatment. However, the present study 
may have been underpowered to demon&ate any beoekial 
effeUsofcaptopriiinlargeandaLsosmaliinfamtions.Pmspeck 
studii using presp&ied strata with di#er;nt infarct sizes are 
needed to address this question. 
11. GNppoRaliaooperloStudio&uaSrreptoehiaasinell’fnfartoMioeardioo-3 
(GISSI). GISSIJ: effeds of Ii&c@ ami tmwkmai glyccqittirdtmte 
singlyandtogetberon6wePkmonalityandMntricularfimmonafleracute 
mycwdkl it&d& lancet 1994;343:1115-22. 
12.AautefnfaruhRamiprilE1Gcaey(AfRE)study~~of 
mmiprilottmunaulyandmorbidigd~ dmttentyoadd 
iruktim with din&l evidemx d heart tkilmt. Lawa 1993$Q%21-8. 
13.K&~.lH,vanGikWH,Pe&KH,Lk3mbkkJ~Ve~FWA 
Wilinga RP. Acute iotetwttb -.qb qtoprii during throorbotysis itt 
patkOtSkth6rstaDteriormpcardralinfarctiResUlOfmmcbe~ 
and Thmmw Study (CATS). Eur Heart I 19%;1%398-%?7. 
14. vandcr~AKntbofPLAl~cr.~F,etrLRe~beheaiofva 
sizeandldlvmiadarperforma~~ffsesseditt~witltlirst~ 
ltlyadd--tohamaonaytsmmbdytL*mpyor 
to amveotional treatment Am 1 chtdid 19t?wl:l-7. 
IS. Gol&temH.E&entstat&kalm&liqofofdata.dahH~ 
Bid 1986$3:12¶-41. 
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